The Clinical Scope of Disopyramide Seven Years After Introduction -- An Overview

Willis III, Park W.
February 1987
Angiology;Feb1987 Part 2, Vol. 38, p165
Academic Journal
Disopyramide phosphate, seven years after its introduction, has proved to be a useful and effective Type IA oral agent for treatment of ventricular arrhythmias. The experience of these seven years has amplified and more sharply defined the initial efficiency and safety issues related to the use of the agent. This experience now shows that disopyramide is at least as effective as other agents in its class and that it can be used safely in the majority of patients for whom treatment is indicated if therapeutic guidelines are followed. The areas of effectiveness, comparative effectiveness, side effects and toxicity of this agent are summarized and guides to patient selection are presented in this review article.


Related Articles

  • A Review of the Effects of Disopyramide Phosphate on Left Ventricular Function and the Peripheral Circulation. Di Bianco, Robert; Gottdiener, John S.; Singh, Steven N.; Fletcher, Ross D. // Angiology;Feb1987 Part 2, Vol. 38, p174 

    In the absence of preexistent myocardial dysfunction, the risk of producing cardiac decompensation in patients being treated with any of the conventional antiarrhythmic agents is low. The availability of disopyramide for clinical use in 1977 produced optimism for an effective antiarrhythmic...

  • Pharmacologic Evaluation of Standard and Controlled-Release Disopyramide. Siddoway, Lyle A.; Barbey, J. Toby; Roden, Dan M.; Woosley, Raymond L. // Angiology;Feb1987 Part 2, Vol. 38, p184 

    Controlled-release disopyramide offers many potential advantages over the standard formulation for improved patient compliance, possible reduction of concentration-related adverse effects, and predictability of pharmacologic effect. The pharmacology of disopyramide, potential advantages and...

  • The Pharmacokinetic and Pharmacodynamic Effects of Varying the Free Fraction of Disopyramide. Shaw, Leslie M.; Doherty, John U.; Waxman, Harvey L.; Josephson, Mark E. // Angiology;Feb1987 Part 2, Vol. 38, p192 

    We have evaluated the influence of several factors on the binding of disopyramide to protein in human serum using a new ultrafiltration system and the enzyme multiplied immunoassay technique (EMIT) for disopyramide immuno-assay. From these studies and those of other investigators, we conclude...

  • Long-Term Use of Controlled-Release Disopyramide in Patients with Severe Ventricular Arrhythmias. Paulk Jr., E. Alan // Angiology;Feb1987 Part 2, Vol. 38, p198 

    Controlled-release (CR) disopyramide phosphate has been available for the past four years for the management of patients with ventricular arrhythmias. The advantages of this preparation over the earlier form have for most patients been striking Improved patient compliance as regards dosing, ease...

  • Transfer from Immediate-Release Disopyramide to Controlled-Release Disopyramide. DiPersio, David M.; Chow, Moses S. S. // Angiology;Feb1987 Part 2, Vol. 38, p188 

    Simulation of serum disopyramide concentrations during transfer from steady-state immediate-release (IR) disopyramide to a sustained-release disopyramide preparation was performed based on pharmacokinetic parameters obtained from fit disopyramide and serum concentrations measured following an...

  • Enantioselective binding of disopyramide to α1-acid glycoprotein and its variants. Kishino, S.; Itoh, S.; Nakagawa, T.; Miyazaki, K. // European Journal of Clinical Pharmacology;Oct2001, Vol. 57 Issue 8, p583 

    Objective: α1-Acid glycoprotein (AAG) has three main genetic variants, F1, S, and A variants. There are few reports on the correlation between AAG variants and binding activity of drug enantiomers. We studied the differences between the binding characteristics of enantiomers of disopyramide...

  • Rythmodan Retard.  // Royal Society of Medicine: Medicines;2002, p483 

    The article presents information on rhythmodan retard, a proprietary, prescription-only preparation of the anti-arrhythmic disopyramide. It is available as modified-release tablets.

  • Class 1-A (Quinidine, Procainamide, Disopyramide).  // Cardiovascular Pharmacology Manual;2008, p40 

    The article presents information about several class 1-A anti-medications, they include quinidine, procainamide and disopyramide. One of their uses is for the management of different kinds of atrial and ventricular arrhythmia. Their adverse effects include hypotension, anorexia, blurred vision...

  • Disopyramide Plasma Concentrations Following Single and Multiple Doses of the Immediate- and Controlled-Release Capsules. Karim, Aziz; Schubert, Elliot N.; Burns, Thomas S.; Palmer, Michael; Zinny, M. A. // Angiology;Jun1983, Vol. 34 Issue 6, p375 

    The article discusses disopyramide plasma concentrations following single and multiple doses of the immediate- and controlled-release capsules. Disopyramide phosphate is a type 1 antiarrhythmic drug used for suppression and prevention of recurrence of specific cardiac arrhythmias. It is freely...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics